Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) revealed Wednesday financial results for the fourth quarter and full year ended Dec. 31, 2021. Q4 Finanical HIghlights
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 9:01 AM
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 9:06 AM
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
February 9, 7:16 AM
HC Wainwright & Co. analyst Patrick Trucchio downgrades Arena Pharmaceuticals (NASDAQ:ARNA) from Buy to Neutral and lowers the price target from $120 to $100.
December 21, 6:13 AM
Cantor Fitzgerald analyst Alethia Young downgrades Arena Pharmaceuticals (NASDAQ:ARNA) from Overweight to Neutral and raises the price target from $93 to $100.
Benzinga’s Bulls And Bears Of The Past Week: Pfizer, Bank Of America, Beyond Meat, GameStop, AMC, Overstock And More
December 18, 2:54 PM
Benzinga has examined the prospects for many investor favorite stocks over the past week.
The Week In Cannabis: Pfizer, Visa, $730M+ In Financings, Malta, EU, Columbia Care, MedMen, Uruguay And More
December 17, 5:15 PM
Below is a recap of the main news related to the cannabis industry and markets for the week of December 13, 2021. Contents